Lykos Moves Forward in Psychiatry After FDA MDMA Setback for PTSD Treatment

Friday, 16 August 2024, 12:05

PTSD-related innovations are in focus as Lykos restructures following FDA's denial of MDMA therapy. The company aims to advance treatments for PTSD despite setbacks. By reducing staffing and engaging with stakeholders, Lykos seeks to continue its mission in psychiatric care.
Ajmc
Lykos Moves Forward in Psychiatry After FDA MDMA Setback for PTSD Treatment

Strategic Reorganization to Enhance MDMA Therapy Development

Lykos Therapeutics is committed to advancing innovative treatments for post-traumatic stress disorder (PTSD) through a strategic reorganization. Following the FDA's recent rejection of its new drug application for MDMA capsules, the company is realigning its focus towards psychiatry and enhancing its clinical development efforts.

Workforce Adjustment and Continued Efforts

  • Reducing workforce by approximately 75% to streamline operations.
  • Focusing remaining team on clinical development, medical affairs, and FDA engagement.

Independent Advisory Board for Guidance

As part of its restructuring, Lykos has established an Independent Advisory Board. This board will guide the company in ensuring effective collaboration with behavioral health facilities and support organizations, particularly for veterans and survivors of sexual violence. Lykos's ongoing mission remains centered on addressing PTSD through innovative therapies.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Get the most reliable and up-to-date financial news with our curated selections. Subscribe to our newsletter for convenient access and enhance your analytical work effortlessly.

Subscribe